24 studies found for:    10-i-0004
Show Display Options
Rank Status Study
1 Completed VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
Condition: Influenza, Human
Intervention: Biological: VRC-FLUDNA056-00VP
2 Completed Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs
Condition: HIV Infection
3 Terminated Sensorimotor Based Brain Computer Interface
Condition: Healthy Volunteers
Intervention: Other: Brain computer Interface Mu (SMR) rhythm
4 Completed
Has Results
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
Conditions: Prostatic Neoplasms;   Metastases, Neoplasm
Interventions: Drug: ZD4054 10 mg;   Drug: ZD4054 15 mg;   Drug: ZD4054 22.5 mg
5 Completed S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: cisplatin;   Drug: etoposide;   Drug: tirapazamine;   Radiation: radiation therapy
6 Recruiting An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BG00012 (dimethyl fumarate)
7 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Pemetrexed;   Biological: Ipilimumab;   Drug: Erlotinib;   Drug: Gefitinib
8 Completed Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma
Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Biological: filgrastim;   Radiation: yttrium Y 90 ibritumomab tiuxetan;   Procedure: peripheral blood stem cell transplantation
9 Completed
Has Results
Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers
Conditions: Congenital Bleeding Disorder;   Healthy
Interventions: Drug: vatreptacog alfa (activated);   Drug: placebo
10 Completed
Has Results
Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder
Condition: Manic or Mixed Episode Associated With Bipolar I Disorder
Interventions: Drug: olanzapine;   Drug: lithium;   Drug: valproate;   Drug: carbamazepine
11 Recruiting A Study of LY3002813 in Participants With Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: LY3002813-IV;   Biological: LY3002183-SC;   Drug: Placebo-IV
12 Completed
Has Results
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
Condition: HIV Infections
Interventions: Drug: nevirapine IR;   Drug: nevirapine XR
13 Active, not recruiting A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
Condition: Schizophrenia
Interventions: Drug: bitopertin [RO4917838];   Drug: Placebo
14 Active, not recruiting Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: midazolam;   Drug: BI 201335;   Drug: tenofovir;   Drug: caffeine;   Drug: tolbutamide;   Drug: pegylated interferon;   Drug: BI 207127;   Drug: ribavirin
15 Completed A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment
Conditions: Postherpetic Neuralgia (PHN);   Peripheral Nerve Injury (PNI);   Non-diabetic Painful Peripheral Polyneuropathy
Interventions: Drug: Qutenza;   Drug: Pregabalin
16 Recruiting Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
Conditions: Obesity;   Short Stature
Interventions: Drug: Niacin;   Drug: Placebo
17 Active, not recruiting A Study in Participants With Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib;   Drug: Methotrexate;   Drug: Placebo;   Drug: Folic Acid
18 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Conditions: Cancer;   Solid Tumor
Intervention: Drug: Pembrolizumab
19 Unknown  Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites
Conditions: Wound Healing;   Wound Infection
Interventions: Device: The exSALT™ SD7 Wound Dressing;   Device: Xeroform® Petrolatum Dressing
20 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Condition: Multiple Myeloma
Interventions: Biological: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Indicates status has not been verified in more than two years